Suriclone

Summary

Suriclone (CHEMBL2105561) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 478 Da · C20H20ClN5O3S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105561
Name	Suriclone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	40903
Molecular formula	C20H20ClN5O3S2
Molecular weight	478
InChIKey	RMXOUBDDDQUBKD-UHFFFAOYSA-N

SMILES: CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3

IUPAC name: [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate

Also known as: Celexane, RP 31264, RP-31264, Suriclona, Suriclone, Suril, SURICLONE

Patent coverage: 644 distinct patent families (2,577 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,575 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).